Cefemax

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefemax

What is Cefemax? Overview

Property Description
Active Ingredient Cefepime hydrochloride (INN)
Form Lyophilized powder for injection
Pharmacological Class Fourth-generation cephalosporin antibiotic
General Purpose Anti-infective agent against serious bacterial illnesses
Origin Synthetic beta-lactam compound

What Type of Anti-Infective Medicine is Cefemax?

Cefemax is a powerful, synthetic antibiotic medication, classified pharmacologically as a fourth-generation cephalosporin, which belongs to the larger group of beta-lactam antibiotics. The active ingredient in the medicine is Cefepime hydrochloride (INN), the chemical essence of the drug substance. Clinical pharmacological studies confirm Cefepime is structurally engineered to be particularly effective against a wide broad range of bacterial pathogens. Cefepime's position as a fourth-generation agent grants it an extended spectrum of activity, including against certain resistant organisms. This unique status makes it a clinically recognized option when a comprehensive and reliable antibacterial intervention is required for serious conditions.


Cefemax Composition and Pharmaceutical Form

Cefemax is supplied as a sterile, lyophilized powder designed specifically for reconstitution into an injectable solution. This single-component product ensures that the active substance, Cefepime hydrochloride, is delivered in a pure and concentrated form. The dosage form dictates that it must be administered parenterally (IV or IM) to ensure rapid and high therapeutic levels in the bloodstream, a distinguishing feature from oral antibiotics. The product's sterile powder format ensures extended stability and immediate readiness for use in acute hospital settings.


General Action and Benefit

The core function of Cefepime is its ability to directly eliminate targeted bacteria, an action recognized in pharmacology as bactericidal. This is achieved by the drug interfering with the integrity of the bacterial cell wall synthesis. This beta-lactam mechanism provides effective defense against bacterial proliferation. This decisive, cell-killing action provides the essential therapeutic benefit of efficiently controlling and clearing the presence of bacterial pathogens in severe systemic infections.

Regulatory References

  1. NIH - Cefepime Entry
  2. DailyMed - Cefepime Label

What side effects are possible with Cefemax?

Possible Side Effects and Safety Information

The safety profile of Cefemax (cefixime) is documented across government regulatory sources, highlighting common reactions and serious risks.

Common and Serious Adverse Reactions

The most frequently reported adverse reactions are generally related to the gastrointestinal system. These commonly include diarrhea (reported at an incidence of 16% in trials), nausea (around 7%), and loose stools. Other reactions involving various system-organ classes include headache, dizziness, and rash.

Of greater clinical significance are rare but serious adverse reactions documented through clinical trials and postmarketing surveillance:

  • Severe Hypersensitivity: This includes the risk of anaphylactic reactions, which can be fatal. Caution is mandated due to the documented potential for cross-hypersensitivity in patients with a history of penicillin allergy.
  • Gastrointestinal Complications: The development of Clostridium difficile-associated diarrhea (CDAD) is a serious risk that may occur during or several weeks after treatment has stopped.
  • Neurotoxicity: Rare cases of seizures and other signs of neurotoxicity have been reported, primarily in patients whose dosage was not properly adjusted for renal impairment.
  • Blood and Liver Effects: Official labeling includes reports of transient hematologic changes (e.g., leukopenia, thrombocytopenia, prolonged prothrombin time) and transient elevations in liver enzymes, hepatitis, or jaundice.
  • Severe Skin Reactions: Rare, life-threatening skin conditions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), have been reported as postmarketing events.

Population-Specific Safety Considerations

A critical safety restriction involves patients with kidney impairment (renal impairment). The dose must be adjusted in patients with reduced kidney function to mitigate the risk of drug accumulation, which can lead to neurotoxicity, including seizures.

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes overdose manifestations and required emergency actions based strictly on government regulatory documents.

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Encephalopathy, including confusion, hallucinations, stupor, and coma; Myoclonus; Seizures; and Nonconvulsive status epilepticus.
Physiological systems affected Primarily the Central Nervous System (CNS), resulting in neurotoxicity.
Dose-related or exposure-related factors Overdose risk is significantly increased by unadjusted doses in the setting of impaired renal function (Creatinine Clearance le 60 mL/min).
Population-specific overdose notes Geriatric patients with renal insufficiency are explicitly noted in official warnings as a population with increased risk for serious neurologic reactions.
Emergency-response statements Patients who receive an overdose should be carefully observed and provided supportive treatment. Hemodialysis is documented to aid in the removal of the drug from the systemic circulation.
When immediate medical help is required Immediate medical attention is required when severe neurological signs are observed, such as collapse, seizure activity, coma, or trouble breathing.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Overdose can lead to Serious neurologic adverse reactions, which may be life-threatening or fatal.
Regulatory basis FDA Prescribing Information and Drug Safety Communications.

Connection to the Overall Overdose Profile

Government documents define the Cefemax overdose profile by the risk of severe CNS toxicity, including nonconvulsive status epilepticus. The profile explicitly links the occurrence of these events to circumstances involving high systemic drug exposure due to poor clearance in renal failure. Management is officially described as being supportive, with hemodialysis listed as a key procedural measure to facilitate drug removal from the body.

Therapeutic Uses of Cefemax

What Cefemax treats: main uses and benefits

Cefemax is primarily used to address serious bacterial infections, providing support when symptoms are related to heightened systemic imbalance. This medication is commonly used in the management of severe systemic illness.

It is utilized to manage the profound and serious signs of widespread bacterial infection, including high fever and systemic discomfort associated with illnesses such as septicemia (bloodstream infection) and meningitis. It is also applicable in conditions presenting with acute organ and tissue involvement, such as moderate to severe pneumonia and complicated urinary tract infections (UTIs), including kidney infections. This intervention is considered relevant for symptomatic management when patients are at their most susceptible to severe complications, such as in cases of febrile neutropenia.

“It helps address symptom clusters that may become intense or disruptive, supporting stability during high-risk phases.”

Quick Fact: Relief for Systemic Discomfort

This medication may assist with supporting functional stability and contributes to reducing the overall symptom burden during periods where symptoms create noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus Drug Information overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cefemax

Contraindications: Who Must Not Use This Medicine

Cefemax (cefixime) is strictly contraindicated for any patient with a known history of hypersensitivity or allergy to:

  • Cefixime or any of the product's inactive ingredients.
  • Other antibiotics in the cephalosporin class.
  • Any history of severe allergy (like anaphylaxis) to any other beta-lactam antibiotic (e.g., penicillins or carbapenems).

Restricted and Special Consideration Populations

Population / Condition Eligibility Status
Infants (under 6 months) Safety and efficacy have not been established.
Renal Impairment Restricted use: Dose adjustment is mandatory for creatinine clearance lt 60 mL/min. Use is not recommended in pediatric patients with renal insufficiency.
Penicillin Allergy Use with caution due to the risk of cross-allergenicity.
Pregnancy Use is restricted to when clearly needed or considered essential by the physician. (Pregnancy Category B)
Lactation (Breastfeeding) Consideration should be given to discontinuing nursing temporarily during treatment.
Phenylketonuria (PKU) The chewable tablet form contains phenylalanine and may worsen this condition.

Overall Eligibility Profile

Cefemax is generally approved for adults and pediatric patients aged six months and older. The most critical restriction is the absolute prohibition for patients with documented allergies to cephalosporins or other severe beta-lactam allergies. For all other patients, eligibility is contingent on factors like age (not established below six months) and renal function, which necessitates careful dose adjustment to ensure safe use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cefemax (cefixime) can interact with certain medicinal products and affect the results of specific laboratory tests. Official regulatory information highlights the following clinically significant interactions:


Interacting Medicinal Products

Category Specific Agent(s) Observed Effect / Mechanism (Official Statement)
Anticoagulants Warfarin and derivatives Concomitant use has been reported to increase prothrombin time, with or without clinical bleeding. Close monitoring is advised for patients, especially those with renal impairment, poor nutritional status, or those previously stabilized on anticoagulant therapy.
Anticonvulsants Carbamazepine Elevated carbamazepine plasma levels have been reported in post-marketing experience. Drug monitoring may be useful to detect alterations in carbamazepine concentrations.

Drug/Laboratory Test Interactions

Cefemax may interfere with certain lab tests, leading to false results:

  • Urine Glucose Tests: A false-positive reaction for glucose in the urine may occur when using tests based on copper sulfate (such as Benedict's or Fehling's solutions). It is recommended to use glucose oxidase-based enzymatic tests.
  • Coombs' Test: A false-positive direct Coombs' test has been reported during treatment with cephalosporins; therefore, a positive result should be recognized as potentially being due to the drug.

Mechanism of Action

Cefemax (Cefepime) is a beta-lactam antibiotic with a primary target of the bacterial cell wall synthesis machinery. It functions as a covalent inhibitor by binding to a set of bacterial enzymes known as Penicillin-Binding Proteins (PBPs), specifically transpeptidases, which are located in the bacterial cytoplasmic membrane.

This binding event occurs at the active site of the PBPs, mimicking the D-Ala-D-Ala substrate, thereby inhibiting the essential transpeptidation step in the final stage of peptidoglycan cross-linking. The consequent molecular pathway is the failure to properly assemble the rigid, mesh-like peptidoglycan layer. This intracellular consequence leads to structural defects in the cell wall integrity and dysregulation of cellular osmoregulation. The downstream cascade results in the activation of bacterial autolytic enzymes and ultimately, cell lysis. At the system level, this mechanism of action mediates a bactericidal effect on susceptible microorganisms.

Dosage and Administration Information

Official Administration Guidelines

Cefemax (Cefepime hydrochloride) is used as an intravenous (IV) or intramuscular (IM) injection, strictly following regimens established by regulatory authorities. The primary and most common route for all major approved uses is IV infusion, typically administered in a supervised clinical setting.


Dosing and Frequency

The specific dosage and frequency are determined by the severity of the condition and the patient’s renal function. For adults with normal kidney function (Creatinine Clearance, CrCL, greater than 60 mL/min):

Indication Context Standard Adult Dose Frequency
Moderate Infections 1 g to 2 g Every 12 hours (q12h)
Severe/Febrile Neutropenia 2 g Every 8 hours (q8h)

Treatment duration is typically fixed, ranging from 7 to 14 days, with 10 days being standard for conditions like moderate pneumonia. For complicated intra-abdominal infections, Cefemax must be used in combination with metronidazole.


Procedural Requirements

As a lyophilized powder for injection, Cefemax requires sterile reconstitution and dilution before administration. The final solution is delivered via IV infusion over a period of approximately 30 minutes.

Critically, the drug is cleared by the kidneys, mandating a dose reduction or interval extension for all adult patients with renal impairment (CrCL le 60 mL/min) as specified in the official prescribing information. Dosage for pediatric patients (2 months to 16 years) is based on body weight (50 mg/kg per dose), not exceeding the maximum recommended adult dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefemax

Evidence for Use in Febrile Neutropenia

Cefemax (Cefepime) was studied for use as an initial empirical antibiotic treatment in patients with febrile neutropenia. Research was evaluated in Randomized Controlled Trials (RCTs), which compared Cefepime monotherapy to other standard antibiotics or to antibiotic combinations. These trials primarily research examined adults and children with serious underlying conditions like hematologic malignancy. Studies monitored outcomes such as the rate of fever resolution and other acute symptom changes (clinical response) and the rate of antibiotic regimen modification (treatment failure). Findings describe patterns observed in the studies regarding these clinical response rates. Trials research explored patterns of clinical response compared to other broad-spectrum agents.

Evidence for Use in Complicated Urinary Tract Infections (cUTIs) and Pyelonephritis

The evidence for Cefemax in complicated urinary tract infections (cUTIs), which include kidney infections (pyelonephritis), comes primarily from large Phase 3 RCTs. The research was evaluated in hospitalized adults with infections that were complex or caused by particularly hard-to-treat bacteria. The studies monitored a Composite Success outcome, which was defined as a specific level of microbiologic eradication (reduction of bacteria) and the resolution of the patient's symptoms (clinical cure). Research highlights the patterns measured during the study period.

What Is Still Uncertain About Cefemax Research

While a significant body of research exists, several areas of uncertainty and limitation remain in the broader evidence landscape. Evidence quality varies across studies, and synthesizing results can be complicated by the fact that trial designs and dosing strategies have changed over time. Findings were mixed regarding how Cefemax compares to specific other high-level antibiotics (like carbapenems) on the outcome of all-cause mortality, making comparative evidence uncertain in this specific context. The long-term effects are not fully established, as most research focuses on the immediate outcome of the acute infection phase.

Key Studies & References

  1. Cefepime (Monograph) - NIH National Library of Medicine (NLM)

Frequently Asked Questions (FAQ)

Common questions about Cefemax (FAQ)


Q: Is Cefemax considered a strong antibiotic?

A: Regulatory information classifies Cefemax as a fourth-generation cephalosporin antibiotic. This class of medicine is identified as a synthetic antibiotic with an extended spectrum of activity, which includes coverage against certain resistant microorganisms.


Q: How quickly does Cefemax reach its highest concentration in the blood?

A: Cefemax is typically administered via intravenous (IV) infusion. According to clinical pharmacology data, Cefemax typically reaches its peak concentration in the blood approximately 30 minutes after the start of the IV infusion.


Q: How long does the effect of Cefemax last in the body?

A: The time it takes for the body to eliminate half of the drug, known as the elimination half-life, is about 2.0 hours in healthy individuals. The drug is typically administered on a fixed schedule (such as every 8 or 12 hours) to maintain consistent therapeutic levels.


Q: Can Cefemax treat viral infections?

A: Cefemax is an antibacterial agent and is not effective against viral infections, according to official product information. It is intended only for infections that are proven or strongly suspected to be caused by bacteria.


Q: What should I do if I miss a dose of Cefemax?

A: Regulatory patient instructions suggest that if a dose is missed, it can be administered as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is typically skipped. These recommendations are general and should be confirmed by a healthcare provider. The instructions note that extra doses should not be administered to compensate for a missed dose.


Q: Is it normal to feel tired or dizzy when taking Cefemax?

A: Official drug labeling lists headache and dizziness as reported adverse reactions. Serious effects like confusion or seizures have been reported, primarily in individuals with reduced kidney function.


Q: Can Cefemax affect your sleep?

A: Official safety data indicates that Cefemax can cause central nervous system effects. These can include disturbances of consciousness or confusion. Since these effects involve disturbances of consciousness, they may impact a patient's normal sleep pattern.


Q: Is Cefemax safe for use in children?

A: Cefemax is approved for use in pediatric patients aged 2 months to 16 years, with specific administration guidelines. Regulatory authorities state that safety and effectiveness have not been established for infants younger than 2 months of age.


Q: Does Cefemax lose effectiveness over time if the full course isn't completed?

A: Official patient counseling emphasizes the importance of completing the full course of treatment, even if symptoms begin to improve quickly. Stopping the antibiotic prematurely may result in the infection not being fully cured and could contribute to the development of antibiotic resistance.


Q: Why do doctors often prescribe Cefemax for respiratory infections?

A: Cefemax is officially indicated for the treatment of certain moderate to severe forms of pneumonia. This is due to its effectiveness against specific susceptible bacteria, including Streptococcus pneumoniae and Pseudomonas aeruginosa.


Q: Is a slight headache a common side effect of Cefemax?

A: Yes, headache is reported as a common adverse reaction in official regulatory documents. It is reported to occur in 1% or more of patients in clinical trials.


Q: How can I tell the difference between a side effect and an allergic reaction to Cefemax?

A: Official labeling distinguishes between common adverse reactions (like headache or diarrhea) and a severe hypersensitivity (allergic) reaction. Severe allergic reactions, such as anaphylaxis, are listed in the Warnings section of the product information and are considered events that warrant immediate attention.


Q: Is Cefemax effective against Staphylococcus bacteria?

A: Official indications show Cefemax can be used for uncomplicated skin and skin structure infections caused by specific susceptible bacteria, including methicillin-susceptible isolates of Staphylococcus aureus.


Q: Why is it important to take Cefemax at the same time each day?

A: Cefemax is administered on a fixed, scheduled basis. The fixed administration schedule is intended to maintain consistent therapeutic drug concentrations in the bloodstream, which is necessary for the medication to be effective against the infection.


Q: Does Cefemax need to be taken with food?

A: No. Cefemax is supplied as a powder prepared for injection (intravenously or intramuscularly). Since it bypasses the digestive system, taking it with or without food is not a factor for its absorption or effectiveness.


Q: How does Cefemax affect the body's 'good' bacteria?

A: As with many antibiotics, Cefemax can alter the balance of the normal bacteria, or flora, that live in the colon. This change in the normal flora can sometimes lead to the overgrowth of Clostridioides difficile bacteria, which is a documented cause of antibiotic-associated diarrhea.


Q: What is the half-life of Cefemax in the average person?

A: The half-life refers to the time it takes for the body to eliminate half of the drug. According to the Clinical Pharmacology section of the official label, the average elimination half-life of Cefemax in healthy adults is approximately 2.0 hours.


Q: Why do some people report a metallic taste after taking Cefemax?

A: Official documentation mentions an altered sense of taste, medically termed dysgeusia, as a rare adverse reaction. This may manifest as a noticeable or metallic taste in the mouth following the administration of Cefemax.


Q: What are the most common side effects people report with Cefemax?

A: The most frequently reported adverse reactions are generally related to the gastrointestinal system. These commonly include diarrhea (reported with an incidence of 16% in trials) and nausea (reported around 7%). Other common reactions include headache and rash.


Q: Does Cefemax cause stomach problems or diarrhea?

A: Yes, gastrointestinal issues are common. Official reports highlight diarrhea and nausea as frequently occurring adverse reactions. More serious issues, like Clostridium difficile-associated diarrhea, are a documented risk that can occur during or after treatment.


Q: Can older adults safely take Cefemax?

A: Official information emphasizes that for all adults, including older adults, careful consideration must be given to kidney function, as dosage adjustment may be needed in cases of renal impairment.


Q: Is Cefemax safe to use during pregnancy?

A: Cefemax is categorized as Pregnancy Category B. Its use is generally limited to situations where the prescribing healthcare provider determines it is clearly necessary or essential for treatment.


Q: Does Cefemax interact with birth control pills?

A: Specific interactions with hormonal birth control pills are not mentioned in the official regulatory documents regarding Cefemax. The label only details interactions with agents such as Warfarin and Carbamazepine.


Q: Does Cefemax interact with any over-the-counter pain relievers?

A: The official product labeling for Cefemax details clinically significant interactions with certain prescription drugs, such as Warfarin and Carbamazepine. However, it does not explicitly mention interactions with common over-the-counter pain relievers.


Q: Why might a doctor switch me to Cefemax if a previous antibiotic failed?

A: Cefemax is a fourth-generation cephalosporin with an extended spectrum of activity. Its unique profile makes it a recognized clinical option when a comprehensive antibacterial intervention is required, such as when dealing with resistant bacteria.


Q: Is Cefemax commonly used for urinary tract infections (UTIs)?

A: Research and official labeling support the use of Cefemax for complicated urinary tract infections (cUTIs), which include kidney infections (pyelonephritis).

How should Cefemax be stored and disposed of?

The storage and disposal instructions for Cefemax (Cefepime) are governed by specific regulatory guidelines for temperature, stability, and handling.


Storage Conditions

Unreconstituted Powder

The dry powder for injection must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). Excursions are permitted up to 30 C.

Reconstituted Solutions

Solutions prepared for infusion are stable for up to 24 hours at controlled room temperature or for up to 7 days when stored under refrigeration (2 C to 8 C). Solutions that have been frozen and thawed must not be refrozen or force-thawed, and must be protected from light in certain containers.

Child Safety

Cefemax must be stored out of the sight and reach of children.


Disposal Instructions

Any unused medicinal product and waste material must be disposed of in accordance with local requirements and regulations. If a drug take-back program is unavailable, non-flushable medicines should be mixed with an undesirable substance, sealed, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefemax found in:

A-Z Index: